The market for microarrays continues to grow, thanks to demand from direct-to-consumer genetics companies, as well as researchers who now favor using lower-complexity arrays in larger studies, according to Illumina CEO Jay Flatley.

Because of this demand for lower-complexity chips, Illumina has set aside earlier plans to debut higher-density whole-genome genotyping arrays containing up to 20 million variants, Flatley said during a presentation at Bank of America Merrill Lynch's Global Healthcare Conference, held last week in Las Vegas.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.